Compare Cassava Sciences Inc (FLNA) vs Gitlab Inc (GTLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Gitlab Inc — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Gitlab Inc trades at $54.8 (market cap $8.92B). The key difference: Gitlab Inc is far larger — about 226.4× Cassava Sciences Inc's market cap, and Gitlab Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Gitlab Inc for 62 Days on average.
| FLNA | GTLB | |
|---|---|---|
Market Cap | $39.40M | $8.92B |
Volume | 759,018 | 4,716,893 |
Sector | Health | Technology |
52-Week High | $4.64 | $53.56 |
52-Week Low | $0.68 | $19.42 |
Typical Hold Time | 37 Days | 62 Days |
Enterprise Value | -$43.28M | $7.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).
The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.
GitLab (GTLB) trades at $51.99, up 0.7% on the day and near its 52-week high, supported by a bullish technical outlook and strong Q2 2026 earnings beats. Revenue growth accelerated to 21.3% year-over-year, with the company raising full-year guidance amid robust AI-driven demand for its DevSecOps platform. However, the stock trades at a high P/E ratio of 521.22, reflecting premium valuation despite negative net income margins.
The investment case hinges on GitLab's execution in monetizing AI and enterprise expansion, but risks include sustained profitability challenges and competitive pressure. Analysts are mixed with a Hold consensus, yet recent news highlights sales momentum and institutional interest, suggesting potential upside if growth targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →
